The striking growth inhibitory effect of 8-Cl-cAMP has been related to its selective binding and activation of cAMP-dependent protein kinase (PKA) isozymes: It binds to RII regulatory subunit with a high affinity for Site B but with a low affinity for Site A, keeping type II PKA in the holoenzyme form, while binding with moderately high affinity for both Site A and Site B to RI regulatory subunit, facilitating dissociation of the RI subunit and down-regulation of type I PKA. The cellular events underlying growth inhibition and differentiation of cancer cells induced by 8-Cl-cAMP include a rapid nuclear translocation of RII-beta, and such translocation of RII-beta into the nucleus correlates with an increase in transcription factors in cancer cells that bind specifically to cAMP response element (CRE). The RI and RII are distinguished by their autophosphorylation and nuclear translocation properties. RII has an autophosphorylation site at a proteolytically sensitive hinge region around the R and C interaction site while RI has a pseudo-phosphorylation site. The RII but not the RI contains a nuclear location signal, K K R K. Overexpression of the RII-beta through an expression vector in several cancer cell lines results in a striking shift in PKA isozyme distribution, growth arrest, differentiation, and reverse transformation. The growth inhibition and reverse transformation correlates with nuclear translocation of RII-beta, as the mutant RII- beta which fails to translocate into the nucleus is incapable of inducing reverse transformation. cAMP through the activation of PKA, is involved in transcriptional regulation in eukaryotic cells. In this mechanism of action, cAMP does not alter the binding affinity of CRE- binding proteins to the CRE. In contrast, cAMP enhances the CRE-binding of the catabolite repressor protein (CAP) in prokaryotic cells and regulates the transcription of several operons. The structural similarity of the cAMP-binding sites in CAP and RII subunit of PKA suggests the possibility of a similar role for RII in eukaryotic gene regulation. Here we report that RII-beta subunit of PKA is a transcription factor capable of interacting physically and functionally with the CRE. In contrast to CREB/ATF, the binding of RII-beta to a CRE was enhanced by cAMP, and in addition, RII-beta exhibited transcriptional activity as a Gal4-RII-beta fusion protein. These experiments identify RII-beta as a component of an alternative pathway for regulation of CRE-directed transcription in eukaryotic cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC008281-16
Application #
6100906
Study Section
Special Emphasis Panel (LTIB)
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Nesterova, M; Johnson, N; Cheadle, C et al. (2006) Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762:398-403
Cho-Chung, Yoon S (2006) Autoantibody biomarkers in the detection of cancer. Biochim Biophys Acta 1762:587-91
Cho-Chung, Y S (2005) DNA drug design for cancer therapy. Curr Pharm Des 11:2811-23
Nesterova, Maria V; Cho-Chung, Yoon S (2004) Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis. Clin Cancer Res 10:4568-77
Cho-Chung, Yoon S (2004) Antisense protein kinase A RI alpha-induced tumor reversion: portrait of a microarray. Biochim Biophys Acta 1697:71-9
Kim, Young Hoon; Lim, Do Sun; Lee, Ji Hye et al. (2003) Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 35:336-49
Cheadle, Chris; Cho-Chung, Yoon S; Becker, Kevin G et al. (2003) Application of z-score transformation to Affymetrix data. Appl Bioinformatics 2:209-17
Cho-Chung, Yoon S (2003) CRE-enhancer DNA decoy: a tumor target-based genetic tool. Ann N Y Acad Sci 1002:124-33
Mani, S; Goel, S; Nesterova, M et al. (2003) Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci 1002:252-62
Cho-Chung, Yoon S; Becker, Kevin G (2003) A genome-wide view of antisense. Nat Biotechnol 21:492

Showing the most recent 10 out of 13 publications